Titan Pharmaceuticals receives FDA communication on ropinirole implant IND
Titan Pharmaceuticals announced the FDA has completed its initial review of the ropinirole implant Investigational New Drug Application (IND) and has requested that Titan hold the initiation of the clinical study pending submission of the requested information and the agency's 30-day review. February 27, 2017